Great Point Partners LLC
- SEC CIK
- 0001281446
- Latest filing
- Aug 14, 2026
Holdings in Q2 2024
Holdings as of Jun 30, 2024, filed Aug 14, 2024. Long positions only; changes compare share counts with Q1 2024.
- Positions
- 33
- −2 vs. Q1 2024
- Portfolio value
- $522.0M
- −$119.6M (−18.6%) vs. Q1 2024
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| LXRXLexicon Pharmaceuticals, Inc. | COM NEW | 30,000 | $50.4K | <0.1% | +30,000 | New | History |
| ANABAnaptysbio, Inc | COM | 25,000 | $626.5K | 0.1% | −951,981−97.4% | Reduced | History |
| SYRESpyre Therapeutics, Inc. | COM NEW | 134,612 | $3.16M | 0.6% | +9,612+7.7% | Added | History |
| KYTXKyverna Therapeutics, Inc. | COM | 499,152 | $3.74M | 0.7% | +349,152+232.8% | Added | History |
| PBYIPuma Biotechnology, Inc. | COM | 1,486,544 | $4.85M | 0.9% | +142,916+10.6% | Added | History |
| BBOTBridgeBio Oncology Therapeutics, Inc. | CL A ORD SHS | 500,000 | $5.11M | 1.0% | 00.0% | Unchanged | History |
| VTGNVistagen Therapeutics, Inc. | COM | 1,529,338 | $5.32M | 1.0% | −329,397−17.7% | Reduced | History |
| TCRXTScan Therapeutics, Inc. | COM | 940,831 | $5.50M | 1.1% | +940,831 | New | History |
| VRDNViridian Therapeutics, Inc. | COM | 500,000 | $6.50M | 1.2% | −835,000−62.5% | Reduced | History |
| TERNTerns Pharmaceuticals, Inc. | COM | 1,149,406 | $7.83M | 1.5% | −160,569−12.3% | Reduced | History |
| OLMAOlema Pharmaceuticals, Inc. | COM | 796,880 | $8.62M | 1.7% | +796,880 | New | History |
| JSPRJasper Therapeutics, Inc. | COM NEW | 402,015 | $9.13M | 1.7% | −5,535−1.4% | Reduced | History |
| AUTLAutolus Therapeutics plc | SPON ADS | 3,441,667 | $12.0M | 2.3% | +2,275,000+195.0% | Added | History |
| OTLKOutlook Therapeutics, Inc. | Stock | 1,701,510 | $12.6M | 2.4% | +221,510+15.0% | Added | History |
| VYGRVoyager Therapeutics, Inc. | COM | 1,601,527 | $12.7M | 2.4% | +1,601,527 | New | History |
| ESPREsperion Therapeutics, Inc. | COM | 5,791,594 | $12.9M | 2.5% | −2,208,406−27.6% | Reduced | History |
| OPTNOptiNose, Inc. | COM | 13,727,097 | $14.3M | 2.7% | +4,940,779+56.2% | Added | History |
| FOLDAmicus Therapeutics, Inc. | COM | 1,495,500 | $14.8M | 2.8% | 00.0% | Unchanged | History |
| CNTXContext Therapeutics Inc. | COM | 7,419,355 | $14.9M | 2.8% | +7,419,355 | New | History |
| IONSIonis Pharmaceuticals Inc | COM | 330,000 | $15.7M | 3.0% | +330,000 | New | History |
| KALVKalVista Pharmaceuticals, Inc. | COM | 1,338,568 | $15.8M | 3.0% | +1,338,568 | New | History |
| ZURAZura Bio Ltd | CLASS A ORD SHS | 4,642,241 | $16.2M | 3.1% | +1,884,501+68.3% | Added | History |
| INSMINSMED Inc | COM PAR $.01 | 250,000 | $16.8M | 3.2% | −525,585−67.8% | Reduced | History |
| DNTHDianthus Therapeutics, Inc. | COM | 757,929 | $19.6M | 3.8% | +132,929+21.3% | Added | History |
| CYTKCytokinetics Inc | COM NEW | 474,202 | $25.7M | 4.9% | +272,000+134.5% | Added | History |
| EOLSEvolus, Inc. | COM | 2,451,772 | $26.6M | 5.1% | +1,772+0.1% | Added | History |
| DVAXDynavax Technologies Corp | COM NEW | 2,374,000 | $26.7M | 5.1% | +1,109,080+87.7% | Added | History |
| ACLXArcellx, Inc. | COMMON STOCK | 492,000 | $27.2M | 5.2% | +192,000+64.0% | Added | History |
| PLRXPliant Therapeutics, Inc. | COM | 2,636,864 | $28.3M | 5.4% | +785,000+42.4% | Added | History |
| MRUSMerus N.V. | COM | 523,288 | $31.0M | 5.9% | +300,000+134.4% | Added | History |
| ABVXAbivax S.A. | SPONSORED ADS | 2,472,188 | $32.7M | 6.3% | −16,295−0.7% | Reduced | History |
| NGNENeurogene Inc. | COM | 1,004,291 | $36.5M | 7.0% | 00.0% | Unchanged | History |
| URGNUroGen Pharma Ltd. | COM | 2,906,259 | $48.8M | 9.3% | +285,714+10.9% | Added | History |
Sold out since Q1 2024 (9)
Positions held at the end of Q1 2024 that are gone from this filing.
| Security | Class | Shares in Q1 2024 | Value in Q1 2024 | % of portfolio in Q1 2024 | History |
|---|---|---|---|---|---|
| ALPNAlpine Immune Sciences, Inc. | COM | 1,128,499 | $44.7M | 7.0% | History |
| APGEApogee Therapeutics, Inc. | COM | 400,000 | $26.6M | 4.1% | History |
| JBIOJade Biosciences, Inc. | COM | 887,690 | $26.2M | 4.1% | History |
| XENEXenon Pharmaceuticals Inc. | COM | 456,148 | $19.6M | 3.1% | History |
| DFTXDefinium Therapeutics, Inc. | Stock | 2,000,000 | $18.8M | 2.9% | History |
| OCULOcular Therapeutix, Inc | COM | 1,728,723 | $15.7M | 2.5% | History |
| ITCIIntra-Cellular Therapies, Inc. | COM | 150,000 | $10.4M | 1.6% | History |
| IMCRImmunocore Holdings plc | ADS | 115,000 | $7.47M | 1.2% | History |
| ARVNArvinas, Inc. | COM | 71,113 | $2.94M | 0.5% | History |